Results from 3 phase 3 studies unveiled Saturday showed that investigational treatment for hyperlipidemia, evolocumab, significantly lowered low-density lipoprotein (LDL) cholesterol, that the results ...

PARIS, France—Eight weeks of evolocumab (Repatha; Amgen) added to a regimen of high-intensity statins following an ACS event was safe and vastly reduced LDL cholesterol levels compared with statins ...

Data From Phase 3 RUTHERFORD-2 Study Show Evolocumab Significantly Reduced Mean LDL-C by 59-66 Percent Compared to Placebo in Patients With Heterozygous Familial Hypercholesterolemia Evolocumab is an ...

(UPDATED) The US Food and Drug Administration (FDA) has permitted new labelling claims for evolocumab (Repatha, Amgen), making it the first PCSK9 inhibitor to be indicated for the prevention of ...

Data From Three Separate Phase 3 Studies of Evolocumab (AMG 145), a PCSK9 Inhibitor, Presented as Featured Clinical Research at ACC.14 Positive Results From the Long-Term Safety and Efficacy Study ...

Data From Phase 3 TESLA Study in Patients With Homozygous Familial Hypercholesterolemia (HoFH) and Phase 2/3 TAUSSIG Study in Patients With Severe Familial Hypercholesterolemia Presented in ...

Cholesterol bloodstream An undesirable lipoprotein effect of LDL apheresis is the lowering of high-density lipoprotein (HDL) cholesterol. Proprotein convertase subtilisin/kexin type 9 (PCSK9) ...